The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

被引：0

作者：

Chiappella, Annalisa ^{[1
]}

Dodero, Anna ^{[2
]}

Evangelista, Andrea ^{[3
]}

Re, Alessandro ^{[4
]}

Orsucci, Lorella ^{[5
]}

Usai, Sara Veronica ^{[6
]}

Castellino, Claudia ^{[7
]}

Stefoni, Vittorio ^{[8
]}

Pinto, Antonio ^{[9
]}

Zanni, Manuela ^{[10
]}

Ciancia, Rosanna ^{[11
]}

Ghiggi, Chiara ^{[12
]}

Rossi, Francesca Gaia ^{[13
]}

Arcari, Annalisa ^{[14
]}

Ilariucci, Fiorella ^{[15
]}

Zilioli, Vittorio Ruggero ^{[16
]}

Flenghi, Leonardo ^{[17
]}

Celli, Melania ^{[18
]}

Volpetti, Stefano ^{[19
]}

Benedetti, Fabio ^{[20
]}

Ballerini, Filippo ^{[21
]}

Musuraca, Gerardo ^{[22
]}

Bruna, Riccardo ^{[23
]}

Patti, Caterina ^{[24
]}

Leonardi, Francesco ^{[25
]}

Arcaini, Luca ^{[26
,27
]}

Magagnoli, Massimo ^{[28
]}

Cavallo, Federica ^{[29
]}

Tabanelli, Valentina ^{[30
]}

Ciccone, Giovannino ^{[31
]}

Pileri, Stefano A. ^{[32
]}

Corradini, Paolo ^{[33
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Div Hematol & Stem Cell Transplant, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Hematol, Milan, Italy

[3] Unit Clin Epidemiol Citta Salute & Sci Torino, Turin, Italy

[4] ASST Spedali Civili, Dept Hematol, Brescia, Italy

[5] Citte Salute Hosp & Univ, Hematol, Turin, Italy

[6] Osped Oncol Armando Businco, Hematol, Cagliari, Italy

[7] Azienda Osped S Croce & Carle, Div Hematol, Cuneo, Italy

[8] Univ Bologna, Dept Translat & Precis Med, Hematol, Bologna, Italy

[9] Fdn G Pascale, Natl Canc Inst, Dept Hematol & Innovat Therapies, Hematol Oncol & Stem Cell Transplantat Unit,IRCCS, Naples, Italy

[10] Azienda Osped Santi Antonio & Biagio & Cesare Arr, Div Hematol, Alessandria, Italy

[11] Ctr Riferimento Oncol CRO IRCCS, Oncohematol & Stem Cell Transplantat & Cellular T, Aviano, Italy

[12] IRCCS Osped Policlin San Martino, Hematol, Genoa, Italy

[13] Fdn IRCCS Ca Granda, Div Hematol, OM Policlin, Milan, Italy

[14] Osped Guglielmo Saliceto, Hematol Unit, Piacenza, Italy

[15] Azienda Ausl IRCCS Santa Maria Nuova Reggio Emili, Reggio Emilia, Italy

[16] ASST Grande Osped Metropolitano Niguarda, Div Hematol, Milan, Italy

[17] Osped S Maria Misericordia, Hematol, Perugia, Italy

[18] Osped Infermi Rimini, UO Ematol, Rimini, Italy

[19] Presidio Osped Univ Santa Maria Misericordia Udin, ASUFC, Clin Hematol, Udine, Italy

[20] Azienda Osped Univ Verona, Hematol & Stem Cell Transplantat, Verona, Italy

[21] IRCCS Osped Policlin San Martino, Clin Hematol, Dept Internal Med DiMI, Genoa, Italy

[22] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Div Hematol, Meldola, Italy

[23] Osped Maggiore La Carita, Div Hematol, Novara, Italy

[24] Azienda Villa Sofia Cervello, Div Onco Hematol, Palermo, Italy

[25] Azienda Osped Univ Parma, Hematol & CTMO, Parma, Italy

[26] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy

[27] Univ Pavia, Dept Mol Med, Pavia, Italy

[28] IRCCS Humanitas Res Hosp, Hematol, Rozzano Milano, Italy

[29] AOU Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[30] IEO Ist Europeo Oncol IRCCS, Div Diagnost Haematopathol, Milan, Italy

[31] AOU Citta Salute & Sci Torino, Unit Canc Epidemiol, CPO Piemonte, Turin, Italy

[32] IEO Ist Europeo Oncol IRCCS, Hematopathol Div, Milan, Italy

[33] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163824

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6538 / 6539

页数：2

共 46 条

[41] Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JS']JSCT-NHL04)
Murayama, Tohru
Fukuda, Takahiro
Okumura, Hirokazu
Sunami, Kazutaka
Sawazaki, Aiko
Maeda, Yoshinobu
Tsurumi, Hisashi
Uike, Naokuni
Hidaka, Tomonori
Takatsuka, Yoshifusa
Eto, Tetsuya
Tsuda, Hiroyuki
Fujisaki, Tomoaki
Miyamoto, Toshihiro
Tsuneyoshi, Naoko
Iyama, Satoshi
Nagafuji, Koji
Harada, Mine
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (06) : 676 - 685
[42] High Rates of Remission with the Initial Treatment of Oral Selinexor Plus CHOP for Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes Analysis of a Multi-Center Phase II Study in China
Ding, Kaiyang
Ma, Jie
Zhang, Xiaohui
Wang, Chunling
Huang Hongming
Sheng, Lixia
Liu, Hailing
Cao, Lei
Wu, Wei
Li, Jianyong
Fan, Lei
BLOOD, 2023, 142
[43] Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx), Plus Rituximab (R) in Case of B-Cell Lymphoma
Held, Gerhard
Houot, Roch
Avigdor, Abraham
Andre, Marc
Dabrowska-Iwanicka, Anna
Jaeger, Ulrich
Tonino, Sanne
Trneny, Marek
Maria, Gomes da Silva
Gaulard, Philippe
Molina, Thierry Jo
Rosenwald, Andreas
Rymkiewicz, Grzegorz
Fest, Thierry
Tarte, Karin
Loeffler, Markus
Ziepert, Marita
Altmann, Bettina
Poeschel, Viola
Haioun, Corinne
BLOOD, 2019, 134
[44] Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study)
Kita, Ryosuke
Shimada, Kazuyuki
Machida, Ryunosuke
Sekita, Tetsuya
Sasaki, Keita
Ishitsuka, Kenji
Fukuda, Haruhiko
Maruyama, Dai
Munakata, Wataru
Nagai, Hirokazu
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 183 - 188
[45] The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma
Sibon, David
Khater, Sherine
Bruneau, Julie
Brouzes, Chantal
Lhermitte, Ludovic
Molina, Thierry Jo
Cartron, Guillaume
Morel, Veronique
Malamut, Georgia
Chauchet, Adrien
Morschhauser, Franck
Perard, Baptiste
Boulet, Jean-Michel
Gauchy, Anne-Cecile
Cerf-Bensussan, Nadine
Macintyre, Elizabeth A.
Asnafi, Vahid
Cellier, Christophe
Hermine, Olivier
BLOOD, 2021, 138
[46] A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAIPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-DENSE CHEMOTHERAPY CHOP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL)
Vitolo, U.
Chiappella, A.
Brusamolino, E.
Angelucci, E.
Balzarotti, M.
Carella, A. M.
Ciccone, G.
Gaidano, G.
Merli, F.
Pane, F.
Pavone, V.
Rossi, G.
Rigacci, L.
Stelitano, C.
Zaja, F.
Martelli, M.
ANNALS OF ONCOLOGY, 2011, 22 : 106 - 106

← 1 2 3 4 5 →